Zhu Pengxiong, Chen Anqing, Wang Zhe, Ye Xiaofeng, Zhou Mi, Liu Jun, Zhao Qiang
Department of Cardiac Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
J Thorac Dis. 2019 Mar;11(3):909-919. doi: 10.21037/jtd.2019.01.101.
To compare the clinical outcomes between multiple arterial (MA) and single arterial (SA) off-pump coronary artery bypass grafting (OPCAB) when applied to left main coronary disease or three-vessel disease.
A total of 537 patients with left main coronary disease or three-vessel disease underwent MA OPCAB (n=114) or SA OPCAB (n=423) in our center from January 2006 to December 2008. The propensity score matching (PSM) was used to obtain the risk-adjusted outcome. Both the perioperative and long-term results were analyzed.
The median follow-up time was 117 months (interquartile range, 110 to 128 months). There was no statistical difference in postoperative mortality and the volume of drainage. The intensive care unit (ICU) length of stay (LOS) of the MA group was shorter than that of the SA group {1 [1-2] 2 [1-3], P=0.001). In the long term, the mortality (5.7% 17.5%, P=0.006), cardiac mortality (1.0% 8.8%, P=0.008), fatal myocardial infarction (MI) rate (0.0% 6.1%, P=0.015) and incidence of readmission for heart failure (19.8% 37.7%, P=0.003) were lower in the MA group than in the SA group. The distributions of NYHA class (P<0.001) and CCS class (P<0.001) were better in the MA group than in the SA group. There was no significant difference in other outcomes. These results were consistent with the K-M curves of freedom from the adverse events.
MA OPCAB was as safe as SA OPCAB, providing better perioperative recovery and better long-term clinical outcomes in the treatment of left main coronary disease or three-vessel disease.
比较多支动脉(MA)非体外循环冠状动脉搭桥术(OPCAB)与单支动脉(SA)非体外循环冠状动脉搭桥术应用于左主干冠状动脉疾病或三支血管疾病时的临床结果。
2006年1月至2008年12月,共有537例左主干冠状动脉疾病或三支血管疾病患者在本中心接受了MA OPCAB(n = 114)或SA OPCAB(n = 423)。采用倾向评分匹配(PSM)来获得风险调整后的结果。对围手术期和长期结果均进行了分析。
中位随访时间为117个月(四分位间距为110至128个月)。术后死亡率和引流量无统计学差异。MA组重症监护病房(ICU)住院时间短于SA组{1 [1 - 2] 2 [1 - 3],P = 0.001}。长期来看,MA组的死亡率(5.7% 17.5%,P = 0.006)、心脏死亡率(1.0% 8.8%,P = 0.008)、致命性心肌梗死(MI)发生率(0.0% 6.1%,P = 0.0!5)和因心力衰竭再次入院的发生率(19.8% 37.7%,P = 0.003)均低于SA组。MA组纽约心脏协会(NYHA)分级(P < 0.001)和加拿大心血管学会(CCS)分级(P < 0.001)的分布情况均优于SA组。其他结果无显著差异。这些结果与不良事件无发生的Kaplan - Meier曲线一致。
MA OPCAB与SA OPCAB一样安全,在治疗左主干冠状动脉疾病或三支血管疾病时,围手术期恢复更好,长期临床结果更佳。